<DOC>
	<DOCNO>NCT00849355</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( safety ) follow treatment squeme : Ciclophosphamide , Vincristine , lyposomal Doxorrubicine ( Myocet ) Prednisone , combine Rituximab first line treatment patient aggresive No Hodgkin B lymphoma cardiovascular risk</brief_summary>
	<brief_title>Ciclophosphamide , Vincristine , Myocet Prednisone , With Rituximab 1st-Line Treatment Patients With No-Hodgkin B Lymphoma Cardiovascular ( CV ) Risk</brief_title>
	<detailed_description>Phase II , multicenter , open , 1-arm study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Patients histological diagnosis Lymphoma Hodgkin B CD20+ high degree mailgnancy 2 . Patients previously treat 3. stage III IV 4 . Informed consent 5 . At least one measurable injury 6 . Age &gt; 18 7 . ECOG 02 8 . Life expectancy &gt; 6 month 9 . Cardiovascular risk define : Mildmoderate systolic dysfunction , isquemic cardiopathy , diabetes mellitus , hypertension , leave ventricular hypertrophy , cardiac arrhythmia , moderate pulmonar hypertension 10. adequate organic functionallity ( creatinine &lt; 2mg/dl ; bilirubin &lt; 2mg/dl ; ALTASTFA &lt; 5 FSN ; neutrphyls total count &gt; 1.5x 109/l platellet count &gt; 100x1097l ) 11 . Use contraceptive method study + 3 month 1. stage I II IPI=0 2 . Symptomatic tumoral affection Nervous central system 3 . Lymphoma hodgkin B indolent 4 . Lymphoma hodgkin B mantlecell 5 . Lymphoma hodgkin T 6. lymphoprolifertaive syndrome posttransplantation immunosuppression associate 7. cardiovacualr disease symptomatic 8 . Cronic infection acute serious 9. history neoplasia past 5 year 10. able understand study poor protocol adherence 11 . Known Hypersensivity atudy drug 12. pregnant/lactant woman 13 . Previous participation clinicla study past 30 day 14 . Previous treatment antraciclines drug use study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>